One therapeutic approach that could be tested is the use of engineered anti-CD160-GPI mAbs that can engage both CD160-GPI receptors expressed on NK cells and CLL-B cells and FcγRs expressed on NK cells. The gene discussed is GPI; the disease is B-cell chronic lymphocytic leukemia.